VIAF

Virtual International Authority File

Search

Leader     00000nz a2200037n 45 0
001     WKP|Q58419119  (VIAF cluster)  (Authority/Source Record)
003     WKP
005     20241121000206.0
008     241121nneanz||abbn n and d
035 ‎‡a  (WKP)Q58419119‏
024 ‎‡a  0000-0002-0179-1751‏ ‎‡2  orcid‏
035 ‎‡a  (OCoLC)Q58419119‏
100 0 ‎‡a  Jian-min Liu‏ ‎‡c  researcher ORCID ID = 0000-0002-0179-1751‏ ‎‡9  en‏
400 0 ‎‡a  Jian-min Liu‏ ‎‡c  wetenschapper‏ ‎‡9  nl‏
670 ‎‡a  Author's A lower value for quantitative ultrasound at radius is an additional indicator of metabolic syndrome and cardiovascular disease risk‏
670 ‎‡a  Author's An independent positive relationship between the serum total osteocalcin level and fat-free mass in healthy premenopausal women.‏
670 ‎‡a  Author's Analysis of recently identified osteoporosis susceptibility genes in Han Chinese women‏
670 ‎‡a  Author's Association of JAG1 with bone mineral density and osteoporotic fractures: a genome-wide association study and follow-up replication studies.‏
670 ‎‡a  Author's Bone: another potential target to treat, prevent and predict diabetes.‏
670 ‎‡a  Author's Care for diabetes with COVID-19: Advice from China‏
670 ‎‡a  Author's Current issues in the presentation of asymptomatic primary hyperparathyroidism: proceedings of the Fourth International Workshop‏
670 ‎‡a  Author's Follicle-stimulating hormone and estradiol are associated with bone mineral densities and risk of fractures in men with type 2 diabetes mellitus‏
670 ‎‡a  Author's IGF-1 as an early marker for low bone mass or osteoporosis in premenopausal and postmenopausal women‏
670 ‎‡a  Author's Interactions of osteoporosis candidate genes for age at menarche, age at natural menopause, and maximal height in Han Chinese women.‏
670 ‎‡a  Author's Liraglutide, the glucagon-like peptide-1 receptor agonist, has anabolic bone effects in diabetic Goto-Kakizaki rats‏
670 ‎‡a  Author's Management of fracture risk in patients with diabetes-Chinese Expert Consensus‏
670 ‎‡a  Author's MC4R-dependent suppression of appetite by bone-derived lipocalin 2.‏
670 ‎‡a  Author's Primary hyperparathyroidism‏
670 ‎‡a  Author's PTH inhibition rate is useful in the detection of early-stage primary hyperparathyroidism.‏
670 ‎‡a  Author's Raloxifene inhibits bone loss and improves bone strength through an Opg-independent mechanism.‏
670 ‎‡a  Author's Roles for osteocalcin in brain signalling: implications in cognition- and motor-related disorders‏
670 ‎‡a  Author's The association between the baseline bone resorption marker CTX and incident dysglycemia after 4 years‏
670 ‎‡a  Author's The changing clinical patterns of primary hyperparathyroidism in Chinese patients: data from 2000 to 2010 in a single clinical center‏
670 ‎‡a  Author's The cross-talk between the skeleton and energy metabolism.‏
670 ‎‡a  Author's The effects of bisphenol A (BPA) exposure on fat mass and serum leptin concentrations have no impact on bone mineral densities in non-obese premenopausal women‏
670 ‎‡a  Author's The relationship among serum lipocalin 2, bone turnover markers, and bone mineral density in outpatient women.‏
670 ‎‡a  Author's Tumor necrosis factor alpha (TNF-alpha) polymorphisms in Chinese patients with Graves' disease‏
670 ‎‡a  Author's Vitamin D and type 2 diabetes mellitus (D2).‏
670 ‎‡a  Author's What can we learn from the Vitamin D and Type 2 Diabetes (D2d) Study?‏
909 ‎‡a  (orcid) 0000000201791751‏ ‎‡9  1‏
919 ‎‡a  folliclestimulatinghormoneandestradiolareassociatedwithbonemineraldensitiesandriskoffracturesinmenwithtype2diabetesmellitus‏ ‎‡A  Follicle-stimulating hormone and estradiol are associated with bone mineral densities and risk of fractures in men with type 2 diabetes mellitus‏ ‎‡9  1‏
919 ‎‡a  interactionsofosteoporosiscandidategenesforageatmenarcheageatnaturalmenopauseandmaximalheightinhanchinesewomen‏ ‎‡A  Interactions of osteoporosis candidate genes for age at menarche, age at natural menopause, and maximal height in Han Chinese women.‏ ‎‡9  1‏
919 ‎‡a  liraglutidetheglucagonlikepeptide1receptoragonisthasanabolicboneeffectsindiabeticgotokakizakirats‏ ‎‡A  Liraglutide, the glucagon-like peptide-1 receptor agonist, has anabolic bone effects in diabetic Goto-Kakizaki rats‏ ‎‡9  1‏
919 ‎‡a  managementoffractureriskinpatientswithdiabeteschineseexpertconsensus‏ ‎‡A  Management of fracture risk in patients with diabetes-Chinese Expert Consensus‏ ‎‡9  1‏
919 ‎‡a  mc4rdependentsuppressionofappetitebybonederivedlipocalin2‏ ‎‡A  MC4R-dependent suppression of appetite by bone-derived lipocalin 2.‏ ‎‡9  1‏
919 ‎‡a  primaryhyperparathyroidism‏ ‎‡A  Primary hyperparathyroidism‏ ‎‡9  1‏
919 ‎‡a  pthinhibitionrateisusefulinthedetectionofearlystageprimaryhyperparathyroidism‏ ‎‡A  PTH inhibition rate is useful in the detection of early-stage primary hyperparathyroidism.‏ ‎‡9  1‏
919 ‎‡a  raloxifeneinhibitsbonelossandimprovesbonestrengththroughanopgindependentmechanism‏ ‎‡A  Raloxifene inhibits bone loss and improves bone strength through an Opg-independent mechanism.‏ ‎‡9  1‏
919 ‎‡a  rolesforosteocalcininbrainsignallingimplicationsincognitionandmotorrelateddisorders‏ ‎‡A  Roles for osteocalcin in brain signalling: implications in cognition- and motor-related disorders‏ ‎‡9  1‏
919 ‎‡a  associationbetweenthebaselineboneresorptionmarkerctxandincidentdysglycemiaafter4years‏ ‎‡A  The association between the baseline bone resorption marker CTX and incident dysglycemia after 4 years‏ ‎‡9  1‏
919 ‎‡a  changingclinicalpatternsofprimaryhyperparathyroidisminchinesepatientsdatafrom2000to2010inasingleclinicalcenter‏ ‎‡A  The changing clinical patterns of primary hyperparathyroidism in Chinese patients: data from 2000 to 2010 in a single clinical center‏ ‎‡9  1‏
919 ‎‡a  crosstalkbetweentheskeletonandenergymetabolism‏ ‎‡A  The cross-talk between the skeleton and energy metabolism.‏ ‎‡9  1‏
919 ‎‡a  effectsofbisphenolabpaexposureonfatmassandserumleptinconcentrationshavenoimpactonbonemineraldensitiesinnonobesepremenopausalwomen‏ ‎‡A  The effects of bisphenol A (BPA) exposure on fat mass and serum leptin concentrations have no impact on bone mineral densities in non-obese premenopausal women‏ ‎‡9  1‏
919 ‎‡a  relationshipamongserumlipocalin2boneturnovermarkersandbonemineraldensityinoutpatientwomen‏ ‎‡A  The relationship among serum lipocalin 2, bone turnover markers, and bone mineral density in outpatient women.‏ ‎‡9  1‏
919 ‎‡a  tumornecrosisfactoralphatnfalphapolymorphismsinchinesepatientswithgravesdisease‏ ‎‡A  Tumor necrosis factor alpha (TNF-alpha) polymorphisms in Chinese patients with Graves' disease‏ ‎‡9  1‏
919 ‎‡a  vitamin500andtype2diabetesmellitusd2‏ ‎‡A  Vitamin D and type 2 diabetes mellitus (D2).‏ ‎‡9  1‏
919 ‎‡a  whatcanwelearnfromthevitamin500andtype2diabetesd2dstudy‏ ‎‡A  What can we learn from the Vitamin D and Type 2 Diabetes (D2d) Study?‏ ‎‡9  1‏
919 ‎‡a  igf1asanearlymarkerforlowbonemassorosteoporosisinpremenopausalandpostmenopausalwomen‏ ‎‡A  IGF-1 as an early marker for low bone mass or osteoporosis in premenopausal and postmenopausal women‏ ‎‡9  1‏
919 ‎‡a  lowervalueforquantitativeultrasoundatradiusisanadditionalindicatorofmetabolicsyndromeandcardiovasculardiseaserisk‏ ‎‡A  A lower value for quantitative ultrasound at radius is an additional indicator of metabolic syndrome and cardiovascular disease risk‏ ‎‡9  1‏
919 ‎‡a  independentpositiverelationshipbetweentheserumtotalosteocalcinlevelandfatfreemassinhealthypremenopausalwomen‏ ‎‡A  An independent positive relationship between the serum total osteocalcin level and fat-free mass in healthy premenopausal women.‏ ‎‡9  1‏
919 ‎‡a  analysisofrecentlyidentifiedosteoporosissusceptibilitygenesinhanchinesewomen‏ ‎‡A  Analysis of recently identified osteoporosis susceptibility genes in Han Chinese women‏ ‎‡9  1‏
919 ‎‡a  associationofjag1withbonemineraldensityandosteoporoticfracturesagenomewideassociationstudyandfollowupreplicationstudies‏ ‎‡A  Association of JAG1 with bone mineral density and osteoporotic fractures: a genome-wide association study and follow-up replication studies.‏ ‎‡9  1‏
919 ‎‡a  boneanotherpotentialtargettotreatpreventandpredictdiabetes‏ ‎‡A  Bone: another potential target to treat, prevent and predict diabetes.‏ ‎‡9  1‏
919 ‎‡a  carefordiabeteswithcovid19advicefromchina‏ ‎‡A  Care for diabetes with COVID-19: Advice from China‏ ‎‡9  1‏
919 ‎‡a  currentissuesinthepresentationofasymptomaticprimaryhyperparathyroidismproceedingsofthe4internationalworkshop‏ ‎‡A  Current issues in the presentation of asymptomatic primary hyperparathyroidism: proceedings of the Fourth International Workshop‏ ‎‡9  1‏
996 ‎‡2  CYT|AC000526553‏
996 ‎‡2  ISNI|0000000052576870‏
996 ‎‡2  DNB|1140853392‏
996 ‎‡2  LC|nr2007007579‏
996 ‎‡2  NKC|ntk20191049987‏
996 ‎‡2  LC|no2023060053‏
996 ‎‡2  BNF|16951812‏
996 ‎‡2  LC|no2017163971‏
996 ‎‡2  LC|no2018150329‏
996 ‎‡2  BNF|14633771‏
996 ‎‡2  NII|DA11283461‏
996 ‎‡2  CYT|AC000662625‏
996 ‎‡2  BNF|17939171‏
996 ‎‡2  NSK|000702506‏
996 ‎‡2  DNB|124851436‏
996 ‎‡2  ISNI|0000000002067517‏
996 ‎‡2  SIMACOB|154587747‏
996 ‎‡2  CAOONL|ncf11508056‏
996 ‎‡2  ISNI|0000000046411156‏
996 ‎‡2  CAOONL|ncf13702117‏
996 ‎‡2  LC|no2011039137‏
996 ‎‡2  BNF|16575335‏
996 ‎‡2  BIBSYS|9051778‏
996 ‎‡2  LC|no2021035648‏
996 ‎‡2  NSK|000542094‏
996 ‎‡2  LC|no2016013909‏
996 ‎‡2  SUDOC|197382665‏
996 ‎‡2  RERO|A023156743‏
996 ‎‡2  LC|n 2020013769‏
996 ‎‡2  CAOONL|ncf11911819‏
996 ‎‡2  LC|no 95050108‏
996 ‎‡2  SUDOC|156290812‏
996 ‎‡2  DNB|1330973844‏
996 ‎‡2  LC|n 2006041756‏
996 ‎‡2  BNF|16699078‏
996 ‎‡2  LC|n 2022180725‏
996 ‎‡2  J9U|987007457678205171‏
996 ‎‡2  DNB|1081223154‏
996 ‎‡2  J9U|987007380969405171‏
996 ‎‡2  J9U|987007437079305171‏
996 ‎‡2  DNB|1156880874‏
996 ‎‡2  NTA|328586390‏
996 ‎‡2  DNB|1186073691‏
996 ‎‡2  SUDOC|253553946‏
996 ‎‡2  NUKAT|n 2015002796‏
996 ‎‡2  BNF|14557627‏
996 ‎‡2  LC|no2008182245‏
996 ‎‡2  NTA|421484012‏
996 ‎‡2  BNF|16504834‏
996 ‎‡2  SUDOC|188249753‏
996 ‎‡2  ISNI|0000000012593756‏
996 ‎‡2  DNB|1212608135‏
996 ‎‡2  CYT|AC000586744‏
996 ‎‡2  BIBSYS|90786125‏
996 ‎‡2  DNB|122713004X‏
996 ‎‡2  CYT|AC000394250‏
996 ‎‡2  LC|no2012132544‏
996 ‎‡2  CYT|AC000244714‏
996 ‎‡2  ISNI|0000000384000835‏
996 ‎‡2  CAOONL|ncf10588999‏
996 ‎‡2  LC|nr 94022593‏
996 ‎‡2  SUDOC|159246598‏
996 ‎‡2  PLWABN|9814233201705606‏
996 ‎‡2  ISNI|0000000001502070‏
996 ‎‡2  PLWABN|9812677248905606‏
996 ‎‡2  CYT|AC000634218‏
996 ‎‡2  RERO|A027752227‏
996 ‎‡2  NII|DA13836186‏
996 ‎‡2  LC|n 2006095324‏
996 ‎‡2  LC|nr2002016588‏
996 ‎‡2  LC|no2024053334‏
996 ‎‡2  NII|DA10998909‏
996 ‎‡2  DNB|1043864318‏
996 ‎‡2  LC|no2023087632‏
996 ‎‡2  NSK|000164739‏
996 ‎‡2  NTA|153778202‏
996 ‎‡2  LC|n 2024183842‏
996 ‎‡2  NTA|344720756‏
996 ‎‡2  DNB|1020861061‏
996 ‎‡2  LC|no2010109568‏
996 ‎‡2  ISNI|0000000051638021‏
996 ‎‡2  CYT|AC000639353‏
996 ‎‡2  ISNI|0000000454548127‏
996 ‎‡2  BIBSYS|90886645‏
996 ‎‡2  ISNI|0000000423301818‏
996 ‎‡2  CYT|AC000005035‏
996 ‎‡2  ISNI|0000000063381657‏
996 ‎‡2  SUDOC|155252615‏
996 ‎‡2  PLWABN|9812744456205606‏
996 ‎‡2  ISNI|0000000114904092‏
996 ‎‡2  LC|n 2011064561‏
996 ‎‡2  KRNLK|KAC200700448‏
996 ‎‡2  ISNI|0000000084867701‏
996 ‎‡2  DNB|1071756575‏
996 ‎‡2  CYT|AC000634508‏
996 ‎‡2  SUDOC|165664541‏
996 ‎‡2  CYT|AC000652790‏
996 ‎‡2  NUKAT|n 2012042030‏
996 ‎‡2  LC|no2002019396‏
996 ‎‡2  ISNI|0000000085544824‏
996 ‎‡2  SUDOC|060700629‏
996 ‎‡2  LC|nb2002012826‏
996 ‎‡2  DNB|1014105951‏
996 ‎‡2  LC|no2012009720‏
996 ‎‡2  CAOONL|ncf10509635‏
996 ‎‡2  LC|no2023107668‏
996 ‎‡2  SELIBR|368895‏
996 ‎‡2  SUDOC|183867556‏
996 ‎‡2  LC|n 2021029140‏
996 ‎‡2  NII|DA12943023‏
996 ‎‡2  CAOONL|ncf12126644‏
996 ‎‡2  NUKAT|n 2020067598‏
996 ‎‡2  CYT|AC000005589‏
996 ‎‡2  BNF|16517418‏
996 ‎‡2  ISNI|0000000032576160‏
996 ‎‡2  ISNI|0000000499958963‏
996 ‎‡2  BIBSYS|11016004‏
996 ‎‡2  SUDOC|280704879‏
996 ‎‡2  LC|no2019016827‏
996 ‎‡2  DNB|1204948496‏
996 ‎‡2  NII|DA07581488‏
996 ‎‡2  NSK|000294786‏
996 ‎‡2  BNF|12476478‏
996 ‎‡2  LC|no2013071916‏
996 ‎‡2  RERO|A017497806‏
996 ‎‡2  NTA|145977471‏
996 ‎‡2  PLWABN|9813695434905606‏
996 ‎‡2  BIBSYS|11013933‏
996 ‎‡2  LC|no2002021960‏
996 ‎‡2  NTA|141213299‏
996 ‎‡2  LC|no2023057557‏
996 ‎‡2  NYNYRILM|308299‏
996 ‎‡2  ISNI|0000000052633249‏
996 ‎‡2  DNB|1065071884‏
996 ‎‡2  LC|n 83218767‏
996 ‎‡2  LC|no2024052398‏
996 ‎‡2  ISNI|0000000444659835‏
996 ‎‡2  ISNI|0000000064275696‏
996 ‎‡2  ISNI|0000000087575448‏
996 ‎‡2  LC|no2012086847‏
996 ‎‡2  LC|nb2007023612‏
996 ‎‡2  LC|no2010135056‏
996 ‎‡2  ISNI|000000007986686X‏
996 ‎‡2  SUDOC|197583393‏
996 ‎‡2  ISNI|0000000356156437‏
996 ‎‡2  SUDOC|192067184‏
996 ‎‡2  ISNI|0000000048829054‏
996 ‎‡2  PLWABN|9810560300505606‏
996 ‎‡2  DNB|1063077729‏
996 ‎‡2  SUDOC|23409639X‏
996 ‎‡2  SUDOC|077261682‏
996 ‎‡2  ISNI|0000000122799819‏
996 ‎‡2  LC|no2006107178‏
996 ‎‡2  SUDOC|19538539X‏
996 ‎‡2  DNB|122579593‏
996 ‎‡2  DNB|1221557254‏
996 ‎‡2  LC|no2018118618‏
996 ‎‡2  DNB|129358347‏
996 ‎‡2  CYT|AC000244000‏
996 ‎‡2  SUDOC|202986365‏
996 ‎‡2  ISNI|0000000019128347‏
996 ‎‡2  LC|n 2019038886‏
996 ‎‡2  ISNI|0000000047059764‏
996 ‎‡2  RERO|A012520808‏
996 ‎‡2  DNB|1325583480‏
996 ‎‡2  SUDOC|124575277‏
996 ‎‡2  RERO|A005480174‏
996 ‎‡2  DNB|1130818373‏
996 ‎‡2  LC|nr2001021518‏
996 ‎‡2  DNB|173855814‏
996 ‎‡2  SUDOC|240886232‏
996 ‎‡2  LC|n 2016069845‏
996 ‎‡2  CAOONL|ncf11927799‏
996 ‎‡2  LC|no2018167095‏
996 ‎‡2  LC|n 2015071697‏
996 ‎‡2  ISNI|0000000054788121‏
996 ‎‡2  DNB|1013697766‏
996 ‎‡2  PLWABN|9811405956905606‏
996 ‎‡2  PLWABN|9810582320405606‏
996 ‎‡2  BNCHL|10000000000000000809120‏
996 ‎‡2  LC|no2001020418‏
996 ‎‡2  LC|n 80092649‏
996 ‎‡2  LC|no2024093606‏
996 ‎‡2  LC|no2012120810‏
996 ‎‡2  NTA|162644558‏
996 ‎‡2  PLWABN|9810613958205606‏
996 ‎‡2  CYT|AC000638153‏
996 ‎‡2  ISNI|0000000040969060‏
996 ‎‡2  CYT|AC000660874‏
996 ‎‡2  DNB|113266263X‏
996 ‎‡2  CYT|AC000650351‏
996 ‎‡2  DNB|1229631488‏
996 ‎‡2  NUKAT|n 2022032742‏
996 ‎‡2  BIBSYS|1689826982357‏
996 ‎‡2  BNF|17823568‏
996 ‎‡2  BNF|17964394‏
996 ‎‡2  BNC|981058599384506706‏
996 ‎‡2  ISNI|0000000046233273‏
996 ‎‡2  LC|n 85386842‏
996 ‎‡2  ISNI|0000000457623727‏
996 ‎‡2  DNB|1225491843‏
996 ‎‡2  NYNYRILM|46932‏
996 ‎‡2  ISNI|0000000048096516‏
996 ‎‡2  DNB|1053925115‏
996 ‎‡2  NTA|363055266‏
996 ‎‡2  NDL|00799846‏
996 ‎‡2  CYT|AC000214700‏
996 ‎‡2  SUDOC|149285914‏
996 ‎‡2  J9U|987007317649005171‏
996 ‎‡2  ISNI|0000000012203033‏
996 ‎‡2  NKC|ntk20211108757‏
996 ‎‡2  ISNI|0000000443038543‏
996 ‎‡2  SELIBR|232488‏
996 ‎‡2  CAOONL|ncf10014310‏
996 ‎‡2  CYT|AC000468982‏
996 ‎‡2  DNB|120784280X‏
996 ‎‡2  ISNI|0000000420642238‏
996 ‎‡2  BIBSYS|8012621‏
996 ‎‡2  ISNI|0000000078703401‏
996 ‎‡2  SUDOC|255114710‏
996 ‎‡2  NSK|000557127‏
996 ‎‡2  CYT|AC660227‏
996 ‎‡2  NYNYRILM|308335‏
996 ‎‡2  BNF|16682862‏
996 ‎‡2  NII|DA12334105‏
996 ‎‡2  ISNI|0000000073047492‏
996 ‎‡2  SUDOC|033960860‏
996 ‎‡2  LC|n 2020003734‏
996 ‎‡2  NUKAT|n 2018100224‏
996 ‎‡2  NUKAT|n 2009048329‏
996 ‎‡2  ISNI|000000003682167X‏
996 ‎‡2  DNB|1238554601‏
996 ‎‡2  SUDOC|202427293‏
996 ‎‡2  NYNYRILM|308242‏
996 ‎‡2  PLWABN|9810616551105606‏
996 ‎‡2  DNB|1136477993‏
996 ‎‡2  DNB|1106416503‏
996 ‎‡2  LC|no2021137514‏
996 ‎‡2  SUDOC|193975793‏
996 ‎‡2  LC|no2018173315‏
996 ‎‡2  SUDOC|263012530‏
996 ‎‡2  SUDOC|236949748‏
996 ‎‡2  CYT|AC000001320‏
996 ‎‡2  DNB|1236781295‏
996 ‎‡2  ISNI|0000000361150988‏
996 ‎‡2  ISNI|0000000119116132‏
996 ‎‡2  LC|no2002066000‏
996 ‎‡2  NTA|326408649‏
996 ‎‡2  DNB|1072234343‏
996 ‎‡2  PLWABN|9813140046105606‏
997 ‎‡a  0 0 lived 0 0‏ ‎‡9  1‏